BPC-157 vs TB-500: What the Research Compares

People search “BPC-157 vs TB-500” as if the two were one choice. In the published research they are not. This page lays the two summaries side by side so you can see what each body of work tested, in what kind of model, and where a direct comparison is not possible.

Quick facts, side by side

• What each is: BPC-157 is a synthetic peptide of 15 amino acids, with a sequence first drawn from a protein in human gastric juice (Chang et al., 2014). TB-500 is used for two things: thymosin beta-4, a 43-amino-acid protein found in most cells, and a seven-amino-acid fragment of it that the FDA lists as “Thymosin beta-4, fragment (LKKTETQ)”.
• Where the name is clear: “BPC-157” points to one molecule. “TB-500” does not, and a laboratory analysis in 2012 found the acetylated fragment in a product sold under that name (Esposito et al., 2012).
• Evidence for BPC-157: a 2025 systematic review of the musculoskeletal research found 36 studies. 35 were in animals or cells and 1 was in people, a look back at patient charts with no control group. The authors found no clinical safety data (Vasireddi et al., 2025).
• Evidence for TB-500: the fragment has cell and animal studies only. The full protein has animal studies and small Phase 2 human trials (Kleinman and Sosne, 2016).
• Approval: we found no approval for either from the FDA or any other regulator. The FDA lists both among substances that were in category 2 before their nominations were withdrawn.

What the studies tested

Each item below tested one compound. The list is the same work summarized on each compound’s own page.

BPC-157, in animals and cells.

• Rats with a cut knee ligament recovered function and structure better when given BPC-157 over 90 days (Journal of Orthopaedic Research, 2010).
• In rats, a detached Achilles tendon reattached to bone faster, and BPC-157 offset some of the harm corticosteroids caused in that model (Krivic et al., 2006).
• In isolated tendon cells, BPC-157 raised growth hormone receptor levels in a dose- and time-dependent way (Chang et al., 2014).
• A 2019 review reported consistent effects across the animal work and said human efficacy is not confirmed (Gwyer et al., 2019).

TB-500, in animals, cells and people.

• Full protein: applied to skin wounds in rats, new skin cover over the wound rose by 42 to 61 percent, and skin cells in a dish moved faster toward it (Journal of Investigative Dermatology, 1999).
• Full protein and fragment: in diabetic and aged mice the full protein sped wound repair, and the seven-amino-acid fragment gave comparable repair in the aged mice (Wound Repair and Regeneration, 2003).
• Fragment: a 2024 cell study found the fragment itself did not show significant wound-closing activity, while one of its breakdown products did (Rahaman et al., 2024).
• Full protein, in people: a review noted faster repair in Phase 2 trials of patients with pressure ulcers, stasis ulcers and a blistering skin condition (Kleinman and Sosne, 2016). A Phase 2 dry eye trial in 72 adults found no difference from placebo on either main measure (PMID 26056426).

How each is proposed to work

The two ideas do not overlap. For BPC-157, researchers propose an interaction with the signals that control how the body lays down collagen, and with growth factor signals tied to new blood vessel growth at an injury site. The receptor it binds is still an open question. For thymosin beta-4, the main known job is binding actin, the protein cells use to build their inner skeleton and to move. Research suggests that helps the cells that rebuild skin and line blood vessels crawl toward a wound. The short fragment copies the stretch of the protein tied to actin binding (Ho et al., 2012). Both sets of ideas come from animal and cell work.

What cannot be compared

The studies used different models, different injuries and different measures, so a result for one cannot be read against a result for the other. The human-level evidence for TB-500 belongs to the natural protein, not to the research-labeled fragment. The BPC-157 evidence has no controlled human trial behind it at all. Neither body of work is a safety conclusion, and nothing here shows how either compound would act in a person. Each compound has its own page with identity data: BPC-157 and TB-500.

Common questions

Is BPC-157 the same as TB-500?

No. BPC-157 is a synthetic 15-amino-acid peptide with a sequence drawn from a protein in human gastric juice. TB-500 is a name used for thymosin beta-4, a 43-amino-acid protein found in most cells, and for a short synthetic fragment of it.

Which has more research behind it?

They cannot be ranked on one scale. BPC-157 has many animal and cell studies and no controlled human trials. Thymosin beta-4 has animal studies and small human trials, but those used the full protein, not the research-labeled fragment.

Has any study tested BPC-157 and TB-500 together?

None of the studies cited on this page did. Each tested one compound. The page on the two together covers what the literature does and does not say about them as a pair.

Is either one FDA approved?

No. We found no approval for either from the FDA or any other regulator. The FDA lists both among substances that were in category 2 (“may present significant safety risks”) before their nominations were withdrawn, and says it lacks information on whether either would cause harm in people.

Last reviewed 2026-10-23.

For laboratory research use only. Not for human or animal consumption. This page summarizes published studies and is not medical advice.